- About About
-
Medical
Medical
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
-
-
Advocates Descend Upon Annual Meeting of the CND in Vienna
This week the United Nations (UN) Committee on Narcotic Drugs (CND) has their annual meetings in Vienna. The CND is responsible for implementing international drug control treaties as well as the scheduling of drugs. The CND makes decisions about scheduling new substances as well as changing the scheduling. The CND base these decisions on recommendations from the World Health Organization (WHO). The WHO makes their recommendations on the scheduling of drugs only after the Expert Committee on Drug Dependence (ECDD) prepares a critical review document.
Today’s agenda for the CND delegation includes the “Implementation of the international drug control treaties,” where they will discuss “changes in the scope of controlled substances” and “international cooperation to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion.”
It is not clear which substances they will be discussing. However, the UN is following WHO’s recommendation and will not be voting on CBD’s international scheduling status. In December 2017, the ECDD released a critical review document on CBD that stated, “in its pure state, cannabidiol does not appear to have abuse potential or cause harm” and recommended to the UN that it remain out of the scheduling scheme all together.
Cannabis, including medical cannabis and its resin, is currently classified as Schedule I in the U.S. and IV under the UN Single Convention. This scheduling was determined based on a report created by the Health Committee of the League of Nations in 1935. The ECDD is currently working on 4 critical review documents on cannabis that will be discussed at the 40th Expert Committee on Drug Dependence (ECDD) June 4-8, 2018 at the WHO Headquarters in Geneva. This is a special session on cannabis that will include the following “pre-reviews:”
- Cannabis plant and cannabis resin
- Extracts and tinctures of cannabis
- Delta-9-tetrahydrocannabinol (THC)
- Isomers of THC
The outcome of these reports will be presented by the WHO to the CND in future meetings. The CND is made up 53 member states (see breakdown below). Currently 22 CND delegations are from countries with medical cannabis laws.
(a) Eleven for African States* |
(b) Eleven for Asian States* |
(c) Ten for Latin American and Caribbean States* |
(d) Six for Eastern European States |
(e) Fourteen for Western European and other States |
Algeria |
Afghanistan |
Argentina |
Belarus |
Australia |
Burkina Faso |
China |
Brazil |
Croatia |
Austria |
Cameroon |
India |
Chile |
Czech Republic |
Belgium |
Côte d’Ivoire |
Israel |
Colombia |
Kyrgystan |
Canada |
Democratic Republic of Congo |
Iran |
Cuba |
Russian Federation |
France |
Kenya |
Iraq |
Ecuador |
Slovakia |
Germany |
Mauritania |
Japan |
El Salvador |
|
Hungary |
South Africa |
Pakistan |
Guatemala |
|
Italy |
Sudan |
Qatar |
Mexico |
|
Netherlands |
Togo |
Republic of Korea |
Peru |
|
Norway |
Uganda |
Thailand |
Uruguay |
|
Spain |
|
|
|
|
Switzerland |
|
|
|
|
Turkey |
|
|
|
|
United States |
Breakdown of Committee on Narcotic Drugs. Countries in blue have national medical cannabis laws, green have pending laws, and nations that are not highlighted do not have a functioning national medical cannabis program.
*One seat to rotate between the Asian, and the Latin American and Caribbean States every four years
Share